166 related articles for article (PubMed ID: 35666052)
21. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
22. MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.
Aida S; Sonobe Y; Tanimura H; Oikawa N; Yuhki M; Sakamoto H; Mizuno T
Cancer Lett; 2017 Nov; 409():116-124. PubMed ID: 28923400
[TBL] [Abstract][Full Text] [Related]
23. Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer.
Bonazzi VF; Kondrashova O; Smith D; Nones K; Sengal AT; Ju R; Packer LM; Koufariotis LT; Kazakoff SH; Davidson AL; Ramarao-Milne P; Lakis V; Newell F; Rogers R; Davies C; Nicklin J; Garrett A; Chetty N; Perrin L; Pearson JV; Patch AM; Waddell N; Pollock PM
Genome Med; 2022 Jan; 14(1):3. PubMed ID: 35012638
[TBL] [Abstract][Full Text] [Related]
24.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
25. Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing.
Cornillie J; Wozniak A; Li H; Wang Y; Boeckx B; Gebreyohannes YK; Wellens J; Vanleeuw U; Hompes D; Stas M; Sinnaeve F; Wafa H; Lambrechts D; Debiec-Rychter M; Sciot R; Schöffski P
Mol Cancer Ther; 2019 Jun; 18(6):1168-1178. PubMed ID: 30962320
[TBL] [Abstract][Full Text] [Related]
26. Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations.
Friedman AA; Xia Y; Trippa L; Le LP; Igras V; Frederick DT; Wargo JA; Tanabe KK; Lawrence DP; Neuberg DS; Flaherty KT; Fisher DE
Clin Cancer Res; 2017 Aug; 23(16):4680-4692. PubMed ID: 28446504
[No Abstract] [Full Text] [Related]
27. Establishment of a patient-derived xenograft model and cell line of malignant transformation of mature cystic teratoma of the ovary.
Tamauchi S; Suzuki S; Xuboya C; Yoshihara M; Yoshida K; Ikeda Y; Yoshikawa N; Kajiyama H; Kikkawa F
J Obstet Gynaecol Res; 2021 Feb; 47(2):713-719. PubMed ID: 33300248
[TBL] [Abstract][Full Text] [Related]
28. A multidimensional impedance platform for the real-time analysis of single and combination drug pharmacology in patient-derived viable melanoma models.
Seidel D; Rothe R; Kirsten M; Jahnke HG; Dumann K; Ziemer M; Simon JC; Robitzki AA
Biosens Bioelectron; 2019 Jan; 123():185-194. PubMed ID: 30201332
[TBL] [Abstract][Full Text] [Related]
29. Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma.
Broit N; Johansson PA; Rodgers CB; Walpole ST; Newell F; Hayward NK; Pritchard AL
Mol Cancer Res; 2021 Jun; 19(6):991-1004. PubMed ID: 33707307
[TBL] [Abstract][Full Text] [Related]
30. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Rivera M; Fichtner I; Wulf-Goldenberg A; Sers C; Merk J; Patone G; Alp KM; Kanashova T; Mertins P; Hoffmann J; Stein U; Walther W
Neoplasia; 2021 Jan; 23(1):21-35. PubMed ID: 33212364
[TBL] [Abstract][Full Text] [Related]
31. Generation of stable PDX derived cell lines using conditional reprogramming.
Borodovsky A; McQuiston TJ; Stetson D; Ahmed A; Whitston D; Zhang J; Grondine M; Lawson D; Challberg SS; Zinda M; Pollok BA; Dougherty BA; D'Cruz CM
Mol Cancer; 2017 Dec; 16(1):177. PubMed ID: 29212548
[TBL] [Abstract][Full Text] [Related]
32. Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts.
Kuwata T; Yanagihara K; Iino Y; Komatsu T; Ochiai A; Sekine S; Taniguchi H; Katai H; Kinoshita T; Ohtsu A
Cells; 2019 Jun; 8(6):. PubMed ID: 31207870
[TBL] [Abstract][Full Text] [Related]
33. BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.
Kemper K; Krijgsman O; Kong X; Cornelissen-Steijger P; Shahrabi A; Weeber F; van der Velden DL; Bleijerveld OB; Kuilman T; Kluin RJC; Sun C; Voest EE; Ju YS; Schumacher TNM; Altelaar AFM; McDermott U; Adams DJ; Blank CU; Haanen JB; Peeper DS
Cell Rep; 2016 Jun; 16(1):263-277. PubMed ID: 27320919
[TBL] [Abstract][Full Text] [Related]
34. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
35. Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma.
Shi CJ; Xu SM; Han Y; Zhou R; Zhang ZY
Melanoma Res; 2021 Dec; 31(6):495-503. PubMed ID: 34483306
[TBL] [Abstract][Full Text] [Related]
36. Atypical
Dumaz N; Jouenne F; Delyon J; Mourah S; Bensussan A; Lebbé C
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31398831
[TBL] [Abstract][Full Text] [Related]
37. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.
Krepler C; Sproesser K; Brafford P; Beqiri M; Garman B; Xiao M; Shannan B; Watters A; Perego M; Zhang G; Vultur A; Yin X; Liu Q; Anastopoulos IN; Wubbenhorst B; Wilson MA; Xu W; Karakousis G; Feldman M; Xu X; Amaravadi R; Gangadhar TC; Elder DE; Haydu LE; Wargo JA; Davies MA; Lu Y; Mills GB; Frederick DT; Barzily-Rokni M; Flaherty KT; Hoon DS; Guarino M; Bennett JJ; Ryan RW; Petrelli NJ; Shields CL; Terai M; Sato T; Aplin AE; Roesch A; Darr D; Angus S; Kumar R; Halilovic E; Caponigro G; Jeay S; Wuerthner J; Walter A; Ocker M; Boxer MB; Schuchter L; Nathanson KL; Herlyn M
Cell Rep; 2017 Nov; 21(7):1953-1967. PubMed ID: 29141225
[TBL] [Abstract][Full Text] [Related]
38. Repurposing Ponatinib as a Potent Agent against
Han Y; Gu Z; Wu J; Huang X; Zhou R; Shi C; Tao W; Wang L; Wang Y; Zhou G; Li J; Zhang Z; Sun S
Theranostics; 2019; 9(7):1952-1964. PubMed ID: 31037149
[No Abstract] [Full Text] [Related]
39. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
[TBL] [Abstract][Full Text] [Related]
40. Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification.
Hu B; Li H; Guo W; Sun YF; Zhang X; Tang WG; Yang LX; Xu Y; Tang XY; Ding GH; Qiu SJ; Zhou J; Li YX; Fan J; Yang XR
Int J Cancer; 2020 Mar; 146(6):1606-1617. PubMed ID: 31310010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]